A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)

Valle, Luca; Lehrer, Eric J.; Markovic, Daniela; Elashoff, David; Levin-Epstein, Rebecca; Karnes, R.J.; Reiter, Robert E.; Rettig, Matthew B.; Calais, Jérémie; Nickols, Nicholas G.; Dess, Robert T.; Spratt, Daniel E.; Steinberg, Michael L.; Nguyen, Paul L.; Davis, Brian J.; Zaorsky, Nicholas G.; Kishan, Amar U.

doi:10.1016/j.eururo.2020.11.010

Cited by 184 publications

(192 citation statements)

References 34 publications

Supporting

Mentioning

183

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, patients with high SII could benefit from a more extensive approach at SRP, which includes extended lymph node dissection or re-irradiation or systemic therapy if surgery might be not technically feasible. Contrary, for patients with lower preoperative SII valuable option, may be focal therapy, which is associated with lower toxicity [2]. In PCa, the inflammatory burden has previously been linked to carcinogenesis and progression [18].…”

Section: Discussionmentioning

confidence: 99%

“…Radiation therapy is an effective therapy for localized prostate cancer (PCa) with durable local control [1,2]. After primary radiation, however, up to 50% of patients experience biochemical recurrence (BCR), which is associated with subsequent risk of metastasis and PCa-specific death [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

“…After primary radiation, however, up to 50% of patients experience biochemical recurrence (BCR), which is associated with subsequent risk of metastasis and PCa-specific death [3][4][5]. While some of these patients develop distant recurrence, a large proportion would benefit from effective local salvage therapy [2]. One of them is salvage radical prostatectomy (SRP), which offers a possibility of cure, and is associated with 53% 5-year recurrence-free survival (RFS) and over 70% 10-year cancer-specific survival (CSS) [2,6].…”

Section: Introductionmentioning

confidence: 99%

“…While some of these patients develop distant recurrence, a large proportion would benefit from effective local salvage therapy [2]. One of them is salvage radical prostatectomy (SRP), which offers a possibility of cure, and is associated with 53% 5-year recurrence-free survival (RFS) and over 70% 10-year cancer-specific survival (CSS) [2,6]. These favorable long-term outcomes after SRP comes at the cost of potentially significant adverse events, including incontinence, although improvement has been reported in recent years [2,[6][7][8].…”

Section: Introductionmentioning

confidence: 99%

“…The current prediction of outcomes based on clinicopathologic is, however, suboptimal. Considering the growing interest of salvage modalities in radio-recurrent PCa, there is an urgent need to improve risk stratification to guide treatment decision making with respect to radical, focal or systemic therapy [2,5,6]. The Systemic Immune-inflammation Index (SII) is a novel biomarker, which combines three immune cell counts into a simple formula: neutrophils × platelets/ lymphocytes [9].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy

et al. 2021

View full text Add to dashboard Cite

Purpose To examine the predictive and prognostic value of preoperative Systemic Immune-inflammation Index (SII) in patients with radio-recurrent prostate cancer (PCa) treated with salvage radical prostatectomy (SRP). Materials and methods This multicenter retrospective study included 214 patients with radio-recurrent PCa, treated with SRP between 2007 and 2015. SII was measured preoperatively (neutrophils × platelets/lymphocytes) and the cohort was stratified using optimal cut-off. Uni- and multivariable logistic and Cox regression analyses were performed to evaluate the predictive and prognostic value of SII as a preoperative biomarker. Results A total of 81 patients had high preoperative SII (≥ 730). On multivariable logistic regression modeling, high SII was predictive for lymph node metastases (OR 3.32, 95% CI 1.45–7.90, p = 0.005), and non-organ confined disease (OR 2.55, 95% CI 1.33–4.97, p = 0.005). In preoperative regression analysis, high preoperative SII was an independent prognostic factor for cancer-specific survival (CSS; HR 10.7, 95% CI 1.12–103, p = 0.039) and overall survival (OS; HR 8.57, 95% CI 2.70–27.2, p < 0.001). Similarly, in postoperative multivariable models, SII was associated with worse CSS (HR 22.11, 95% CI 1.23–398.12, p = 0.036) and OS (HR 5.98, 95% CI 1.67–21.44, p = 0.006). Notably, the addition of SII to preoperative reference models improved the C-index for the prognosis of CSS (89.5 vs. 80.5) and OS (85.1 vs 77.1). Conclusions In radio-recurrent PCa patients, high SII was associated with adverse pathological features at SRP and survival after SRP. Preoperative SII could help identify patients who might benefit from novel imaging modalities, multimodal therapy or a closer posttreatment surveillance.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy

et al. 2021

View full text Add to dashboard Cite

show abstract

Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell

Diao

Liu

2023

Advanced Science

View full text Add to dashboard Cite

Cancer immunotherapies have improved human health, and one among the important technologies for cancer immunotherapy is cancer vaccine. Antigens are the most important components in cancer vaccines. Generally, antigens in cancer vaccines can be divided into two categories: pre-defined antigens and unidentified antigens. Although, cancer vaccines loaded with predefined antigens are commonly used, cancer vaccine loaded with mixed unidentified antigens, especially whole cancer cells or cancer cell lysates, is a very promising approach, and such vaccine can obviate some limitations in cancer vaccines. Their advantages include, but are not limited to, the inclusion of pan-spectra (all or most kinds of ) antigens, inducing pan-clones specific T cells, and overcoming the heterogeneity of cancer cells. In this review, the recent advances in cancer vaccines based on whole-tumor antigens, either based on whole cancer cells or whole cancer cell lysates, are summarized. In terms of whole cancer cell lysates, the focus is on applying whole water-soluble cell lysates as antigens. Recently, utilizing the whole cancer cell lysates as antigens in cancer vaccines has become feasible. Considering that pre-determined antigen-based cancer vaccines (mainly peptide-based or mRNA-based) have various limitations, developing cancer vaccines based on whole-tumor antigens is a promising alternative.

show abstract

Nonmetastatic castration‐resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy

Yoshida¹,

Matsuoka²,

Toda

et al. 2021

IJU Case Reports

View full text Add to dashboard Cite

Introduction The efficacy of salvage local therapy after external beam radiotherapy has recently gained attention. However, a challenge with these therapies is the risk of significant genitourinary and gastrointestinal toxicity. Focal brachytherapy may be a treatment option because of its potential to reduce side effects. Case presentation A patient with castration‐resistant prostate cancer was found to be free of metastases on whole‐body magnetic resonance imaging following external beam radiotherapy, and prostate biopsy revealed a localized recurrence in the ventral prostate. The patient underwent salvage focal brachytherapy and had a prostate‐specific antigen progression‐free survival of 23 months. No adverse effects were observed following salvage brachytherapy. Conclusion Our case suggests that salvage focal brachytherapy may be an effective local treatment option for nonmetastatic castration‐resistant prostate cancer that has relapsed after external beam radiotherapy, wherein the lesion is confined to a small area within the prostate.

show abstract

A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)

Cited by 184 publications

References 34 publications

Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy

Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy

Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell

Nonmetastatic castration‐resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy

Contact Info

Product

Resources

About